The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant benefits to non-small cell lung cancer patients with EGFR mutations, which represent a breakthrough in lung cancer therapy. However, patients will ultimately develop the acquired resistance to the first- or sec...

Full description

Bibliographic Details
Main Authors: Shiyu Li, Shuangli Zhu, Hongqu Wei, Pengfei Zhu, Ying Jiao, Ming Yi, Juejun Gong, Kun Zheng, Li Zhang
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
EGFR-TKIs
Resistance
Combination therapies
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222013488

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222013488

Similar Items